Abstract
IntroductionThere are few studies and reports, which compared the efficacy and safety between them. We conducted this meta-analysis to identify the effectiveness and safety of olopatadine and ketotifen allergic conjunctivitis. MethodsThe protocol was registered in PROSPERO. We searched Medline, Embase, Web of science, Ebsco and Cochrane library databases through February 2023, and randomized controlled trials (RCTs) were included to assess the therapeutic efficacy of olopatadine versus ketotifen on allergic conjunctivitis. Six RCTs were included in the meta-analysis. Overall, compared with ketotifen intervention for allergic conjunctivitis, olopatadine intervention results in significantly lower itching during 4–7days after medication (MD=−0.55; 95% CI=−0.72 to −0.38; P<0.00001) and during 14days after medication (MD=−0.45; 95% CI=−0.57 to −0.32; P<0.00001), but demonstrated no significant impact on tearing. These suggested that olopatadine may provide better local treatment for allergic conjunctivitis as compared to ketotifen.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
